EntryPoint Capital LLC Buys New Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

EntryPoint Capital LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 4,812 shares of the biopharmaceutical company's stock, valued at approximately $230,000.

Other institutional investors have also recently modified their holdings of the company. Centaurus Financial Inc. acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter worth $127,000. Quantbot Technologies LP purchased a new stake in Halozyme Therapeutics during the third quarter worth about $150,000. Townsquare Capital LLC grew its position in Halozyme Therapeutics by 74.4% during the third quarter. Townsquare Capital LLC now owns 103,223 shares of the biopharmaceutical company's stock worth $5,908,000 after buying an additional 44,044 shares during the period. CreativeOne Wealth LLC purchased a new position in Halozyme Therapeutics in the third quarter valued at about $1,035,000. Finally, Hantz Financial Services Inc. acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $9,260,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Up 1.2 %

Halozyme Therapeutics stock traded up $0.75 during trading on Wednesday, hitting $62.62. The company's stock had a trading volume of 223,423 shares, compared to its average volume of 1,376,117. The stock's fifty day moving average is $59.34 and its 200 day moving average is $54.84. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The stock has a market capitalization of $7.74 billion, a price-to-earnings ratio of 18.26, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

HALO has been the subject of several research analyst reports. Benchmark reaffirmed a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $62.78.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares of the company's stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,200 shares of company stock worth $1,786,668 in the last quarter. 2.90% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.